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Abstract 
Purpose: To investigate the activity and mechanism of action of arbidol against Hantaan virus (HTNV) 
activity by modulating inflammation via TLR-4 pathway. 
Methods: HUVEC cells infected with HTNV 76-118 were treated with serially diluted arbidol solutions at 
-2h (2 h before viral infection, pre-treatment mode), 0 h (at the same time as viral infection, 
simultaneous treatment mode) or 2 h (2 h after viral infection, post-treatment mode). The transcript 
levels of TLR4 were detected by semi-quantitative reverse transcription-PCR (RT-PCR) at 6, 12, 18, 
and 24 h later. The levels of iNOS and TNF-α were examined using enzyme-linked immunosorbent 
assay (ELISA). 
Results: Pre-treatment with arbidol, rather than simultaneous treatment or post-treatment, effectively 
inhibited up-regulation of cellular TLR4 expression (up to 40 ± 6.1 % inhibition) and activity of 
supernatant iNOS induced by HTNV infection(up to 44.1 ± 9.4 % inhibition), as well as in a LPS-
stimulated inflammatory endothelial cell. Arbidol decreased the elevated TNF-α levels induced by LPS 
stimulation.  
Conclusion: These results are the first evidence that arbidol modulates viral PRRs signaling and its 
consequential inflammatory cytokine/chemokine response during hantavirus infection. 
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Hantaviruses belong to the family, Bunyaviridae, 
and are associated with two severe forms of 
hantavirus infections in the human, namely 
hemorrhagic fever with renal syndrome (HFRS) 
and hantavirus pulmonary syndrome (HPS), 
which pose a great threat to human health [1]. 
Ninety percent of the HFRS cases worldwide 
were reported in China and mainly caused by 
two serotypes of hantaviruses-Hantaan virus 
(HTNV) and Seoul virus (SEOV) [2].  
 
At present, there are no antivirals, or vaccines 
approved by the Food and Drug Administration 
(FDA) for the use of hantavirus infection [3]. It is 
urgent to develop antivirals with novel 
pharmacological strategies to overcome 
hantavirus infection. Arbidol is a broad-spectrum 
antiviral compound that has been shown to have 
inhibitory effect on influenza virus [4,5], 
respiratory syncytial virus [6], adenovirus, 
coxsackievirus [7] and hepatitis C virus 
infection[8], as well as hantavirus [9]. The 
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antiviral mechanism of arbidol is not completely 
understood. Early studies indicated that arbidol 
inhibited membrane fusion of enveloped viruses 
[10-12]. Arbidol also acts as an 
immunomodulator, which can induce interferon 
and activate macrophages in viral infectious 
patients [13,14]. Our former study indicates that 
arbidol efficiently inhibits replication of influenza 
virus and diminishes acute inflammation through 
modulating the expression of inflammatory 
cytokines, which indicate the anti-inflammatory 
activity of arbidol [5]. 
 
In a previous study, the present authors 
demonstrated that arbidol can inhibit HTNV in 
vitro and in vivo, and it can modulate the level of 
serum TNF-α in HTNV-infected mouse [9]. Thus, 
we initiated this study to investigate how arbidol 
exhibits its anti-HTNV activity by modulating 
inflammatory effect via TLR-4pathway. 
Furthermore, we also analyzed this effect in an 
acute inflammation cell model stimulated by 





Cells, virus, and reagents 
 
Arbidol was provided by Shijiazhuang NO.4 
Pharmaceutical. Co. Ltd, Hebei, China. HUVEC 
cells were obtained from CHISCIENTIFIC and 
were routinely grown in F-12K supplemented 
with 10 % fetal bovine serum (FBS, GIBCO), 0.1 
% L-glutamine, 100 U/mL penicillin and 
streptomycin. The F-12K containing 2 % FBS 
was used for maintaining medium after viral 
infection. The stocks of Hantaan virus, strain 76-
118 were obtained from the Institute of Virology, 
Chinese Academy of Preventive Medicine 
(Beijing, China) and were propagated on Vero E6 
cells. HTNV titration was performed regularly as 
described previously [9]. Arbidol was provided by 
Shijiazhuang NO.4 Pharmaceutical. Co. Ltd, 
Hebei, China. The compound was initially 
dissolved in 0.05 % dimethyl sulfoxide (DMSO) 




The cytotoxicity of arbidol on HUVEC cells was 
determined by quantitative colorimetric MTT 
assay as described previously [7]. To investigate 
the dynamic expression pattern of TLR4 after 
HTNV infection or LPS stimulation, the HUVEC 
cells were treated with virus or LPS and 
subsequently incubated for 6, 12, 18, and 24 h. 
 
For arbidol treatment, HUVEC cells were infected 
with HTNV 76-118 at 100xTCID50 or LPS (100 
ng/mL, S1732, Beyotime Institute of 
Biotechnology, Shanghai, China), and further 
treated with serially diluted ARB solutions at -2 h 
(2 h before viral infection, pre-treatment mode), 0 
h(at the same time as viral infection, 
simultaneous treatment mode) or 2 h (2 h after 
viral infection, post-treatment mode), 
respectively. After 24 h incubation, the cells were 
collected for RNA detection by RT-PCR. Four 
serial dilutions of arbidol (2.5, 5, 10,20μg/mL) 
were tested in triplicate. Viral control, normal 
control and solvent control were included in all 
assays. Cells in extra wells from each group 
were continuously cultured in corresponding 
medium for 7 days. Immunofluorescence assay 
(IFA) was used to detect viral antigen and 
confirm the successful viral infection in each 
experiment. In the pre-treatment mode, the 
supernatant from each wells were collected for 




Viral RNAs were extracted using TIANamp Virus 
RNA Kit (Tiangen Biotech Co. Ltd., Beijing) 
following the manufacturer’s instructions. First-
strand cDNA was synthesized by reverse 
transcription of the total RNA using random 
primer (Sangon, Shanghai, China) and Moloney 
murine leukemia virus (M-MLV) Reverse 
transcriptase(Promega, Beijing, China). 
Complementary DNA was prepared at 25 oC for 
10 min, 42 oC for 60 min, 95 oC for 5 min 
(Eppendorf, USA).The amplification was 
performed using the following primer sets: TLR4: 
5’-CATTGCTTCTTGCTAAATGCTG-3’ and 5’-
GGATTAAAGCTCAGGTCCAGG-3’; GAPDH: 5’-
GGTGGTCCTCTGACTTCAACA-3’ and  5’-
GTTGCTGTAGCCAAATTCGTTGT-3’, respect-
tively. Thirty-two cycles of PCR were carried out 
in 25 μL reaction mixtures containing 2.5 μL 
synthesized cDNA. A programmed thermal cycler 
was set as follows: 94 oC for 180 s, 94 oC for 
30s, and 60 oC for 30 s, 72 oC for 15 s, and 72 oC 
for 5 min. Thereafter, 6 μL of each PCR product 
was loaded onto an agarose gel containing 
ethidium bromide and separated by 
electrophoresis. The gel was scanned using the 
KODAK Gel Logic 212 PRO Imaging System and 
analyzed using Bandscan 5.0 software, which 
calculates the ratio of peak value adsorption of 
TLR4 to that of GAPDH. 
 
Inducible nitric oxide synthase (iNOS) assay 
 
Inducible nitric oxide synthase (iNOS) activity 
were determined by a NOS assay kit (Cat no. 
A014-1, Nanjing Jiancheng Bioengineering 
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Institute, Nanjing, China) following the 
manufacturer’s instructions. One hundred 
microliter sample of each group was half diluted 
and mixed with 100 μL reaction inhibitor solution 
at room temperature for 3 min. The sample was 
then incubated with reaction buffer at 37 oC for 
15 min. The reaction was terminated by adding 
the stop buffer and the absorbance was 
determined at 530 nm. The activity of iNOS was 
calculated using equation 1: 
 
iNOS activity (U/ml)=(ODsample-ODblank)/(ε × b 
× 1500) …………………………………….……..(1) 
 
The inhibitory effect of arbidol was evaluated by 
the following equation 2:  
 
iNOS inhibitory rate=(iNOS unitArbidol-iNOS 




TNF-α in the supernatant was detected by 
QuantiKine ELISA kit (R&D Systems, 
Minneapolis, MN, USA) according to the 
manufacturer’s instructions. Briefly, 40 μL Assay 
Diluent and 10 μL sample were successively 
added in the microplate and incubated at 37 oC 
for 1 h. Plates were washed with PBS, 200 µL 
Conjugate and 200 µL substrate solution were 
added followed by 15 min incubation at 37 oC. 
The reaction was terminated with stop solution 




Data are presented as mean ± standard 
deviation (SD) and were analyzed by SPSS 17.0 
software. One-way ANOVA was used to 
determine statistical differences for iNOS activity, 
TNF-α level, and mRNA/β-actin ratio. P < 0.05 





Cytotoxicity of arbidol on HUVEC cells 
 
HUVEC cells were treated with arbidol at 
different concentrations varying from 2.5 to 40 
μg/mL and cell viability was investigated by MTT 
assay (Figure 1). Subconfluent monolayers 
treated with arbidol under 10 µg/mL did not show 
any visible changes in cell morphology or cell 
density. The CC50 of arbidol was 17.67 μg/mL. 
 
Effect of arbidol on TLR4 expression in 
HTNV-infected HUVEC cells 
 
We first analyzed the mRNA expression pattern 
of TLR4 in HUVEC infected with HTNV and 
stimulated with LPS. Total RNA was isolated at 6 
h, 12 h, 18 h and 24 h post-inoculation and cDNA 
produced by reverse transcription were subjected 
to PCR analysis. As shown in Figure 2, TLR4 
was expressed at detectable level in both HTNV- 
and LPS- stimulated cells and the expression 
level after HTNV- and LPS-stimulation are 
significantly different from the initial normal 
expression (p < 0.05, except of 6 h in LPS 
group). The expression pattern in these two 
groups were similar (p = 0.2815). 
 
 
Figure 1: Cytotoxicity of arbidol on HUVEC cells.The cytotoxicity of arbidol on HUVEC cells was determined by 
quantitative colorimetric MTT assay. The graph was plotted based on logarithm of drug dosage and the CC50 was 
calculated by Probit regression method 
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Figure 2: Dynamic expression of TLR4 in Hantavirus- and LPS- stimulated HUVEC cells. At 6, 12, 18 and 24 h 
after stimulation, TLR4 expression was determined by semiquatitative RT-PCR as described in Materials and 
methods. (A). representative agarose gel of DNA generated from primers for TLR4 and GAPDH using RT-PCR. 
(B). graphic quantification of the TLR4 mRNA after correction by GAPDH. Relative expression of TLR4 against 
GAPDH. Error bars represent the standard error of mean. The data represents the mean from three independent 
experiments 
 
We further investigated the effect of arbidol on 
TLR4 expression in HTNV-infected and LPS-
stimulated HUVEC cells. Arbidol treatment was 
applied to different modes as described in 
Material and Methods. In the pre-treatment 
mode, arbidol significantly inhibited the up-
regulated TLR4 expression induced by 
hantavirus infection or LPS stimulation (Figure 
3A & B). This effect increased with increase in 
drug concentration. The 20 μg/mL arbidol 
inhibited around 40 ± 6.1 % TLR4 expression in 
HTNV-infected cells, and 50 ± 1.8 % in the LPS 
group (p < 0.05). In the simultaneous treatment 
mode, the inhibitory effect was observed only at 
20 μg/mL in hantavirus infection group (p = 
0.041, Figure 3C) or 10.0 μg/mL and 20 μg/mL in 
LPS stimulation group (p = 0.025, p = 0.028, 
Figure 3D), and not than in the low-concentration 
groups. In the post-treatment mode, TLR4 
expression in HUVEC cells treated with arbidol at 
20 μg/mL showed a significant reduction (p < 
0.01, Figure 3E & F). 
 
Taken together, pre-treatment with arbidol 
inhibited the increased TLR4 expression due to 
hantavirus infection or LPS stimulation in a 
concentration-dependent manner. High dosage 
of arbidol also showed inhibitory effects in the 
other treatment modes. 
 
Effect of arbidol on iNOS in HTNV-infected 
HUVEC cells 
 
To test whether arbidol has an impact on NO 
production, HUVEC cells were first pre-treated 
with different concentrations of arbidol for 2 h, 
and then infected with HTNV or stimulated with 
LPS. Twenty four hours later, the amount of 
nitrite in the supernatant was measured. As 
shown in Figure 4A & B, elevated levels of nitrite 
were detected in the supernatant from HUVEC 
cells after HTNV or LPS stimulation, with 
approximately 2.8- or 5-fold increase compared 
to non-infected cells (p < 0.01). Arbidol 
treatments at concentration of 5 and 10 μg/mL 
inhibited the elevated iNOS with approximately 
30.9 ± 8.1 and 44.1 ± 9.4 % respectively (p < 
0.05).There were no inhibitory effect observed in 
the high concentration group (20 μg/mL) or low 
concentration group (2.5 μg/mL). 
 
Effect of arbidol on TNF-α in HTNV-infected 
HUVEC cells 
 
It is known that TNF-α induces nitric oxide (NO) 
through the induction of NOS, thus we tested 
whether TNF-α was involved in the anti-viral or 
anti-inflammatory effect of arbidol in HTNV-
infected or LPS-stimulated HUVEC cells. The 
results showed that LPS stimulation, rather than 
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HTNV infection, could induce TNF-α production 
3.7 times higher than normal control group (p < 
0.01, Figure 4C & D). Furthermore, arbidol could 
decrease the elevated TNF-α levels induced by 
LPS stimulation in a concentration-dependent 
manner (Figure 4D). 
 
Figure 3: Inhibitory Effect of arbidol on TLR4 expression in Hantavirus- and LPS- stimulated HUVEC cells via 
different modes. HUVEC cells infected with HTNV( A, C, E) or LPS (B, D, F) were treated with serially diluted 
arbidol solutions at -2 h (pre-treatment, A&B), 0 h(simultaneous treatment mode, C & D) or2 h (post-treatment 
mode, E & F), respectively. Y axis represents relative expression of TLR4 against GAPDH in different groups. 
*p<0.05 vs. control group, **p<0.01 vs. control group 
 
 
Figure 4: Effect of arbidol on iNOS activity and TNF-α production in HTNV- and LPS- stimulated HUVEC cells. 
HUVEC cells were treated with serially diluted arbidol solutions for 2h and subsequently infected with HTNV (A, 
C) or LPS (B, D), respectively. The iNOS activity (A, B) and TNF-α production (C, D) in the supernatant were 
measured; *p < 0.05 vs. stimulation group; **p < 0.01 vs. stimulation group 
Xiong et al 




Arbidol is a small antiviral compound with a 
broad-spectrum inhibitory effect. We have 
previously shown that arbidol could inhibit HTNV 
in vitro and in vivo. Here, our results 
demonstrated that arbidol could inhibit the up-
regulation of cellular TLR4 expression as well as 
iNOS induced by HTNV infection, and also 
inflammation stimulated with LPS. 
 
It has been reported that HTNV induces TLR4 
expression in virus-infected EVC-304 cells, 
leading to enhanced production of IFN-β, IL-6 
and TNF-α [15]. Arbidol possesses 
comprehensive pharmacological properties and 
is also known as an immunomodulant and 
interferon inducer. However, Boriskin et al found 
that arbidol inhibited acute HCV infection without 
affecting RIG-I and IFN signaling pathway [8], 
which implied other antiviral mechanisms of 
arbidol besides interferon induction. We found 
that arbidol inhibited the increased TLR4 
expression due to hantavirus infection or LPS 
stimulation, especially in the pre-treatment group 
in a concentration-dependent manner. This result 
suggests that arbidol may regulate the TLR4-
mediated innate immune response in the HTNV-
infected HUVECs. 
 
We further tested if arbidol could modulate the 
inflammatory cytokines/chemokines produced by 
antiviral innate response during HTNV infection. 
Increased amounts of iNOS have been detected 
in patients with hantavirus-related disease, which 
could facilitate immunopathological processes 
during the infection [16,17]. Administration of a 
specific iNOS inhibitor significantly improved 
survival in hantavirus-infected murine model with 
HCPS-like disease [16]. We found that median 
concentration of arbidol could attenuate the 
elevated iNOS level in HTNV- or LPS- stimulated 
HUVECs, which suggests that arbidol may 
alleviate the pathological consequences of HTNV 
infection/acute inflammation via inhibition of 
iNOS generation. 
 
It has been reported that hantavirus infection can 
up-regulate the production of TNF-α in HFRS 
patients [18,19]. Niikura et al demonstrated that 
TNF-α could extend the duration of increased 
vascular permeability of the HTNV-infected 
HUVEC [20]. It could also induce nitric oxide 
(NO) through induction of NOS [21]. We tried to 
examine if arbidol could inhibit the production of 
iNOS via suppression of TNF-α expression. 
However, our results showed that arbidol could 
decrease the elevated TNF-α levels induced by 
LPS stimulation in a concentration-dependent 
manner. We did not detect any change of TNF-α 
in the supernatant of HTNV-infected HUVECs, 
nonetheless, other in vitro studies reported that 
infection of immature dendritic cells or human 
alveolar macrophages with hantavirus weakly up-
regulated TNF-α production.  
 
We assume that the HTNV infection of HUVEC 
itself did not induce TNF-α production as it did in 
other cell lines or the production level is too low 
and beyond the detection range in our system. 
Previously we have found that arbidol could 
modulate TNF-α response in HTNV-infected 
suckling mice [9], we presumed that arbidol may 
modulate the inflammatory chemokine in an 





Arbidol inhibits TLR4 expression and iNOS 
production induced by HTNV infection in 
HUVECs, which represents one of the virus-
sensing pattern-recognition receptors (PRRs) 
and its consequential inflammatory 
cytokines/chemokines. Further experiments are 
needed to investigate the in-depth mechanism of 
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